All articles tagged with #fnip1
A Nature study of over a million people found rare, protein-truncating FNIP1 mutations that lift a cellular energy brake, nudging the body to burn fat, improve fat distribution, and cut cardiometabolic disease risk by about 60%; lab and mouse experiments support the mechanism, suggesting FNIP1 as a potential drug target, though safety and efficacy of inhibiting FNIP1 are not yet proven.
A study of genetic data from over a million people identified a rare FNIP1 gene mutation that turns off calorie-burning pathways, helping about 1 in 7,000 individuals stay lean with lower body fat and healthier metabolic markers. Mouse experiments suggest turning off FNIP1 could inspire future weight‑loss therapies, but risks exist and any treatment would be years away.
In a study of over a million people, researchers found a rare loss‑of‑function FNIP1 mutation carried by about 150 individuals (roughly 1 in 7,000) that causes faster energy burning and less fat storage, with carriers exhibiting lower lipids, less liver fat, lower blood sugar, more muscle, and about 60% lower odds of obesity, diabetes and related diseases. Lab work showed silencing FNIP1 in liver cells activates fat‑burning genes, and mice on a fatty diet with FNIP1 pathway inhibition gained less weight and had better insulin sensitivity. The work suggests FNIP1 could be a target for drugs that mimic these effects, but safety concerns remain—especially with two broken copies—and researchers note any therapy would be years away and may require liver‑focused approaches.
A large genomics study of over one million people links certain FNIP1 gene variants to more muscle, less belly fat, better glucose metabolism and a substantially lower risk of cardiometabolic diseases such as type 2 diabetes and heart disease, suggesting FNIP1 as a potential target for future therapies.
A large exome-sequencing study of 1,032,116 individuals uncovers rare FNIP1 coding variants associated with a favorable energy-metabolism state, measured by the triglyceride-to-HDL ratio. Follow-up experiments in human hepatocytes and mouse liver suggest that perturbing the FNIP–FLCN pathway enhances mitochondrial and lysosomal function and lipid catabolism, with downstream effects on insulin sensitivity and liver fat, offering mechanistic insight into genetic influences on cardiometabolic risk and liver–adipose communication.